CanVIG-UK Resources
Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant
Approved: May 2022
Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant
Approved: May 2022
Example predictive testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant (reduced penetrance)
Approved: May 2022
Example predictive testing template for reporting a positive BRCA1 or PALB2 germline pathogenic/likely pathogenic variant
Approved: May 2022
Previous version: June 2021
Example predictive testing template for reporting a positive BRCA2 germline pathogenic/likely pathogenic variant
Approved: May 2022
Previous version: June 2021
Example predictive testing template for reporting a positive BRCA or PALB2 germline pathogenic/likely pathogenic variant
Approved: May 2022
Previous version (BRCA only): June 2021
Example predictive testing template for reporting a positive BRCA or PALB2 germline pathogenic/likely pathogenic variant (reduced penetrance)
Approved: May 2022
PRED Report Template: R208 Negative
*NEW REPORT*
Example predictive testing template for reporting a negative variant for the R208 germline panel
Approved: May 2022
Previous version: June 2021
Example diagnostic testing template for reporting a CHEK2 or ATM germline pathogenic/likely pathogenic variant.
Approved: May 2022
Example diagnostic testing template for reporting ATM c.7271T>G p.(Val2424Gly)
Approved: May 2022
Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.
Approved: May 2022
Previous version (BRCA only): June 2021
Example diagnostic testing template for reporting a reduced penetrance BRCA or PALB2 germline pathogenic/likely pathogenic variant.
Approved: May 2022
Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.
Approved: May 2022
Example diagnostic testing template for reporting where a variant of uncertain significance (VUS) is identified in the R208 panel (including CHEK2 and ATM)
Approved: May 2022
Previous version (BRCA only): June 2021
Example diagnostic testing template for reporting no germline pathogenic/likely pathogenic variants identified in the R208 panel (including CHEK2 and ATM)
Approved: May 2022
Previous version (BRCA only): June 2021
Example template for reporting a germline pathogenic/likely pathogenic variant in the Ovarian Cancer R207 diagnostic panel.
Approved: June 2022
Previous version: June 2021
Example template for reporting a germline variant of uncertain significance in the Ovarian Cancer R207 diagnostic panel.
Approved: June 2022
Example template for reporting no germline pathogenic/likely pathogenic variants in the Ovarian Cancer R207 diagnostic panel.
Approved: June 2022
Example Report Templates
External Resources
ACGS
The Association for Clinical Genomic Science brings together scientists working within genetics into one professional association.
JMG Paper
Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network.
Journal of Medical Genetics
Published: 13 March 2020.
UKCGG
The UK Cancer Genetics Group.
A multidisciplinary organisation for UK clinicians, counsellors & scientists interested in cancer susceptibility genetics.
ACMG
The American College of Medical Genetics variant interpretation framework can be found on their website.